H
Hiroshi Inagaki
Researcher at Nagoya City University
Publications - 264
Citations - 8018
Hiroshi Inagaki is an academic researcher from Nagoya City University. The author has contributed to research in topics: Lymphoma & MALT lymphoma. The author has an hindex of 43, co-authored 247 publications receiving 7189 citations. Previous affiliations of Hiroshi Inagaki include Nagoya University & Hammersmith Hospital.
Papers
More filters
Journal ArticleDOI
Defucosylated Anti-CCR4 Monoclonal Antibody (KW-0761) for Relapsed Adult T-Cell Leukemia-Lymphoma: A Multicenter Phase II Study
Takashi Ishida,Tatsuro Joh,Naokuni Uike,Kazuhito Yamamoto,Atae Utsunomiya,Shinichiro Yoshida,Yoshio Saburi,Toshihiro Miyamoto,Shigeki Takemoto,Hitoshi Suzushima,Kunihiro Tsukasaki,Kisato Nosaka,Hiroshi Fujiwara,Kenji Ishitsuka,Hiroshi Inagaki,Michinori Ogura,Shiro Akinaga,Masao Tomonaga,Kensei Tobinai,Ryuzo Ueda +19 more
TL;DR: KW-0761 demonstrated clinically meaningful antitumor activity in patients with relapsed ATL, with an acceptable toxicity profile, and further investigation of KW-761 for treatment of ATL and other T-cell neoplasms is warranted.
Journal Article
Clinical Significance of CCR4 Expression in Adult T-Cell Leukemia/Lymphoma: Its Close Association with Skin Involvement and Unfavorable Outcome
Takashi Ishida,Atae Utsunomiya,Shinsuke Iida,Hiroshi Inagaki,Yoshifusa Takatsuka,Shigeru Kusumoto,Genji Takeuchi,Shigeki Shimizu,Masato Ito,Hirokazu Komatsu,Atsushi Wakita,Tadaaki Eimoto,Kouji Matsushima,Ryuzo Ueda +13 more
TL;DR: Investigation of immunostaining analysis for CCR4 and CXCR3 expression in ATLL cells obtained from 103 patients with ATLL revealed a novel insight into not only the biological but also the clinical features of ATLL, and multivariate analysis confirmed that C CR4 expression was an independent and significant prognostic factor.
Journal ArticleDOI
Phase I Study of KW-0761, a Defucosylated Humanized Anti-CCR4 Antibody, in Relapsed Patients With Adult T-Cell Leukemia-Lymphoma and Peripheral T-Cell Lymphoma
Kazuhito Yamamoto,Atae Utsunomiya,Kensei Tobinai,Kunihiro Tsukasaki,Naokuni Uike,Kimiharu Uozumi,Kazunari Yamaguchi,Yasuaki Yamada,Shuichi Hanada,Kazuo Tamura,Shigeo Nakamura,Hiroshi Inagaki,Koichi Ohshima,Hitoshi Kiyoi,Takashi Ishida,Kouji Matsushima,Shiro Akinaga,Michinori Ogura,Masao Tomonaga,Ryuzo Ueda +19 more
TL;DR: KW-0761 was tolerated at all the dose levels tested, demonstrating potential efficacy against relapsed CCR4-positive ATL or PTCL, and subsequent phase II studies at the 1.0 mg/kg dose are thus warranted.
Journal ArticleDOI
Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma.
Michinori Ogura,Takashi Ishida,Kiyohiko Hatake,Masafumi Taniwaki,Kiyoshi Ando,Kensei Tobinai,Katsuya Fujimoto,Kazuhito Yamamoto,Toshihiro Miyamoto,Naokuni Uike,Mitsune Tanimoto,Kunihiro Tsukasaki,Kenichi Ishizawa,Junji Suzumiya,Hiroshi Inagaki,Kazuo Tamura,Shiro Akinaga,Masao Tomonaga,Ryuzo Ueda +18 more
TL;DR: Mogamulizumab exhibited clinically meaningful antitumor activity in patients with relapsed PTCL and CTCL, with an acceptable toxicity profile, and further investigation of mogamulIZumab for treatment of T-cell lymphoma is warranted.
Journal ArticleDOI
Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege.
Takashi Ishida,Toshihiko Ishii,Atsushi Inagaki,Hiroki Yano,Hirokazu Komatsu,Shinsuke Iida,Hiroshi Inagaki,Ryuzo Ueda +7 more
TL;DR: It is shown that migratory CD4(+) cells induced by HL cells were hyporesponsive to T-cell receptor stimulation and suppressed the activation/proliferation of the effector CD4 (+) T cells in an autologous setting.